# Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa

> **NCT01670500** · PHASE2 · COMPLETED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 118 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT01670500
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2019-05
- **Final completion:** 2025-02-02
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01670500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01670500, "Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01670500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*